Dokuz Eylül Üniversitesi Tıp Fakültesi Hastanesi Mikoloji Laboratuvarına Gönderilen Kazıntı Örneklerinin Direk Bakı ve Kültür Sonuçları

Abstract

Objective: Cytomegalovirus (CMV) is the most common viral pathogen isolated in kidney transplant patients. CMV infections may increase the risk of acute rejection, and lead to graft failure, patient death, opportunistic infections, malignancy, diabetes, and cardiovascular complications. Prophylactic antiviral therapy after transplantation is the most effective strategy to reduce the incidence of CMV infections. In this study, we aimed to investigate the incidence of CMV infection and risk factors in kidney transplant recipients who received valganciclovir prophylaxis. Materials and Methods: (35% vs. 21.2%, p>0.05, respectively). The frequency of anti-thymocyte globulin (ATG) use due to acute rejection was significantly higher in the recipients with CMV infection (22.8% vs. 8.7%, p=0.038). In addition, CMV infection occurred in 50% of the patients who were given ATG. Conclusion:CMV infection is a significant cause of morbidity and mortality in transplant recipients and antibody therapies used for induction or rejection are the major factors responsible from development of CMV infection. It will be useful to follow-up CMV-DNA copies regularly in the recipients who receive antibody treatment and effective prophylaxis strategies should be established in these patients.